

## Original Article

# Prevalence and risk factors associated with non-attendance in neurodevelopmental follow-up clinic among infants with CHD

Eméfah C. Locooh,<sup>1</sup> Sunkyoung Yu,<sup>1</sup> Janet Donohue,<sup>1</sup> Ray Lowery,<sup>1</sup> Jennifer Butcher,<sup>2</sup> Sara K. Pasquali,<sup>1</sup> Caren S. Goldberg,<sup>1</sup> Karen Uzark<sup>1</sup>

<sup>1</sup>*Pediatric Cardiology;* <sup>2</sup>*Pediatric Psychology, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, United States of America*

**Abstract** *Background:* Neurodevelopmental impairment is increasingly recognised as a potentially disabling outcome of CHD and formal evaluation is recommended for high-risk patients. However, data are lacking regarding the proportion of eligible children who actually receive neurodevelopmental evaluation, and barriers to follow-up are unclear. We examined the prevalence and risk factors associated with failure to attend neurodevelopmental follow-up clinic after infant cardiac surgery. *Methods:* Survivors of infant (<1 year) cardiac surgery at our institution (4/2011–3/2014) were included. Socio-demographic and clinical characteristics were evaluated in neurodevelopmental clinic attendees and non-attendees in univariate and multivariable analyses. *Results:* A total of 552 patients were included; median age at surgery was 2.4 months, 15% were premature, and 80% had moderate–severe CHD. Only 17% returned for neurodevelopmental evaluation, with a median age of 12.4 months. In univariate analysis, non-attendees were older at surgery, had lower surgical complexity, fewer non-cardiac anomalies, shorter hospital stay, and lived farther from the surgical center. Non-attendee families had lower income, and fewer were college graduates or had private insurance. In multivariable analysis, lack of private insurance remained independently associated with non-attendance (adjusted odds ratio 1.85,  $p = 0.01$ ), with a trend towards significance for distance from surgical center (adjusted odds ratio 2.86,  $p = 0.054$  for  $\geq 200$  miles). *Conclusions:* The majority of infants with CHD at high risk for neurodevelopmental dysfunction evaluated in this study are not receiving important neurodevelopmental evaluation. Efforts to remove financial/insurance barriers, increase access to neurodevelopmental clinics, and better delineate other barriers to receipt of neurodevelopmental evaluation are needed.

**Keywords:** CHD; developmental delay; non-attendance; neurodevelopmental evaluation

Received: 3 July 2017; Accepted: 21 November 2017; First published online: 23 January 2018

**W**ITHIN THE UNITED STATES OF AMERICA, ~40,000 infants are born yearly with CHD.<sup>1</sup> Although survival of infants with CHD has improved markedly over the past several decades owing to enhanced surgical and medical therapies, neurodevelopmental impairments are

common.<sup>2</sup> Children requiring open-heart surgery during the neonatal or infant period are considered at high risk for developmental disorders or disabilities.<sup>3,4</sup> This risk is not based solely on disease severity.<sup>3</sup> Additional risk factors include prematurity, genetic abnormalities, history of mechanical support, cardiopulmonary resuscitation at any point, perioperative procedures, and prolonged hospitalisation.<sup>3</sup> Furthermore, the level of risk can change over time and deficits can present across many domains.<sup>3,5–9</sup> In infants, gross and fine motor

Correspondence to: K. Uzark, PhD, CPNP University of Michigan Mott Children's Hospital, L2108 Women's, SPC 5204, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-5204, United States of America. Tel: 734 615 9748; Fax: (734) 232 3744; E-mail: karenu@med.umich.edu

skills and communication may be most affected, whereas other deficits – that is adaptive, social/emotional, cognitive, and executive functioning – may not become apparent until later in childhood.<sup>3,10–14</sup>

For these reasons, neurodevelopmental evaluation is recommended to improve neurodevelopmental outcomes from birth to adulthood in children with CHD.<sup>3</sup> However, data are lacking regarding the proportion of children who actually receive this important evaluation. Failure to keep outpatient appointments is known to be common across other paediatric populations.<sup>15–17</sup> For example, in neonatal intensive care unit graduates, follow-up rates in high-risk clinics ranged from 28% to <50%.<sup>18,19</sup> Our understanding of barriers to follow-up is also limited. We know that socio-demographic factors have been identified in other paediatric populations.<sup>20,21</sup> In addition, for infants with CHD, specialised follow-up services may only be available at the surgical center and may not be easily accessible locally. The objective of this study was to determine the prevalence of neurodevelopmental evaluation at our institution and to identify risk factors for failure to attend neurodevelopmental follow-up clinic after infant cardiac surgery.

## Materials and methods

### *Study population*

A list of all patients who were discharged after having cardiac surgery within the first year of life at our institution between April 2011 and March 2014 was obtained through our institutional Society of Thoracic Surgeons Congenital Heart Surgery Database. These patients comprised the study population. Infants who did not survive to discharge or died between discharge and the scheduled neurodevelopmental appointment date were excluded.

Our standard practice is to refer all infants who have cardiac surgery between 0 and 12 months of age to our Congenital Heart Center Neurodevelopmental Follow-up Clinic, a programme started in April 2011 to provide neurodevelopmental evaluation including administration of the Bayley Scales of Infant and Toddler Development and review of parent-reported measures of development and psychosocial functioning by a paediatric psychologist. A social worker and dietician are available to meet with families as needed. In addition, since January 2014, initial visits may also include a physical exam focused on neuro-motor assessment by a paediatric nurse practitioner. During the infant's surgical hospitalisation, parents received information about the clinic and infants were referred at discharge. After discharge, parents were contacted by the neurodevelopmental clinic to schedule the infant's evaluation. Since late 2013,

patients are scheduled before discharge. Following the initial visit at 9–12 months of age, follow-up is scheduled at 18–24 months, and 3 years with referral to our school age programme for children over 4 years of age. On the basis of the evaluation, referrals are made to local early intervention or private programmes for physical, occupational, or speech therapies available throughout the region.

### *Study procedures and data collection*

After Institutional Review Board approval with waiver of informed consent, medical records were retrospectively reviewed to retrieve demographic data including age at time of surgery, sex, race, maternal age at time of birth, residence location, insurance type, and cardiologist location and whether affiliated with the surgical center. Clinical data included CHD severity – mild, moderate, or severe as previously described by Wernovsky<sup>22</sup> – and the Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery risk category; comorbid conditions such as prematurity <37 weeks, genetic abnormality or syndrome, seizures, treatment with extracorporeal membrane oxygenation/ventricular assist device, or heart transplantation during initial surgical hospitalisation; and total length of hospital stay.

United States Census block data for place of residence as last designated in the medical record, including family income and parental educational levels, were collected. The University of Michigan Congenital Heart Neurodevelopmental Outcome database was reviewed to ascertain attendance in the Congenital Heart Center Neurodevelopmental Follow-Up clinic at any time during the study period. Individuals who initially cancelled and later attended a Neurodevelopmental clinic follow-up appointment were included as “attendees”.

### *Outcome measures*

The primary outcome was attendance at the scheduled neurodevelopmental clinic appointment for evaluation.

### *Statistical analysis*

The prevalence of neurodevelopmental follow-up was calculated by determining the percentage of survivors following CHD surgery during the study period who attended follow-up appointments at our centre for neurodevelopmental evaluation. Univariate comparisons of clinical and socio-demographic factors were made between attendees and non-attendees to identify factors associated with neurodevelopmental clinic appointment attendance using  $\chi^2$  test or

Fisher's exact test for categorical variables and Wilcoxon rank sum test for continuous variables. Age at time of surgery was also evaluated as dichotomous (age <30 days [neonate] versus  $\geq 30$  days). Other continuous variables including family income, parental educational levels, and hospital length of stay were also examined categorically using the lowest quartile. Distance to surgical center was examined categorically based on the distribution of the variable. Variables found to be significantly associated with non-attendance in univariate analysis ( $p < 0.05$ ) were further evaluated in multivariable logistic regression to assess independent associations with non-attendance. Multicollinearity for the variables included in the multivariable analysis was examined using variance inflation factor. When variance inflation factor is  $>10$ , the variables are considered collinear. The variance inflation factors for all variables included in the model were  $<1.8$ , demonstrating that multi-collinearity is not a problem for this model. A  $p$ -value of  $<0.05$  was considered statistically significant. All analyses were performed using IBM SPSS Statistic 22.

## Results

### Study population

During the study period, 574 infants had cardiac surgery. A total of 22 patients were excluded owing to death before neurodevelopmental evaluation. The remaining 552 had cardiac surgery at a median age of 2.4 months (interquartile range 0.2–4.9); 80% of the patients had moderate or severe CHD. Approximately one-third (32%) received cardiac follow-up at the surgical center and 10% lived  $>200$  miles from our centre. Approximately one-half (51%) had private insurance. Other socio-demographic and clinical characteristics are summarised in Table 1.

### Prevalence of neurodevelopmental follow-up

Overall, 17% (94/552) of infants returned for neurodevelopmental evaluation during the follow-up period, with attendance remaining unchanged across the 3 years of the study, including the final 6 months following a modification of the scheduling process. Year 1 attendance was 21.3%, year 2 attendance was 14%, and year 3 attendance was 15.2%, slightly higher in year 1 with longer follow-up time. Median age at first neurodevelopmental evaluation was 12.4 months, ranging from 9.6 to 48.5 months.

### Univariate analysis

As shown in Table 2, in univariate analysis, non-attendees were older at surgery ( $p < 0.001$ ) and had a

Table 1. Patient/family demographics and clinical characteristics (n = 552)\*

Socio-demographic characteristics	
Male gender	309 (56.0%)
Race	
Caucasian	424 (76.8%)
African-American/Black	53 (9.6%)
Other	75 (13.6%)
Maternal age at infant birth (years)	29.0 (24–33)
Distance to surgical center	
<200 miles	496 (89.9%)
$\geq 200$ miles	56 (10.1%)
Insurance	
Private	282 (51.1%)
High school graduate (GED or Equiv.) (%)**	91.6 (85.5–95.4)
College graduate (%)**	21.7 (12.4–35.9)
Median family income (US\$)**	61,392 (45,694–77,981)
Cardiologist location	
Surgical center	176 (31.9%)
Outside	376 (68.1%)
Clinical characteristics	
Age at time of surgery (months)	2.4 (0.2–4.9)
Prematurity, <37 weeks	84 (15.2%)
Non-cardiac anomaly	150 (27.2%)
Genetic/chromosomal abnormality	143 (25.9%)
Diagnosis severity***	
Mild	113 (20.5%)
Moderate	199 (36.1%)
Severe	240 (43.5%)
STAT category	
Low (categories 1–3)	311 (56.3%)
High (categories 4–5)	241 (43.7%)
Hospital length of stay (days)	
$\leq 8$ days	153 (27.7%)
Perioperative extracorporeal membrane oxygenation	9 (1.6%)
Perioperative seizures/neurological disorders	67 (12.1%)

STAT = Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery

\*Data presented as frequency (%) for categorical variables; median (interquartile range) for continuous variables

\*\*United States Census block data as based off the 2009–2013 American Community Survey

\*\*\*Diagnosis severity as defined in the methods<sup>22</sup>

lower Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery category ( $p = 0.04$ ). Non-attendees also had shorter hospital stays ( $p = 0.02$ ), and were less likely to have seizures/neurological disorders ( $p = 0.02$ ) or non-cardiac anomalies ( $p = 0.01$ ). There was no significant difference between attendees and non-attendees with respect to the presence of a genetic/chromosomal abnormality ( $p = 0.73$ ).

Non-attendees were less likely to have a cardiologist at the surgical center ( $p = 0.004$ ) and more likely to live more than 200 miles from the surgical center ( $p = 0.04$ ). With respect to family characteristics, families of non-attendees were more likely to

Table 2. Univariate comparison of neurodevelopmental follow-up clinic attendees versus non-attendees.

	Attendees (n = 94)	Non-attendees (n = 458)	p-value**
Socio-demographic factors			
Male gender	52 (55.3)	257 (56.1)	0.89
Caucasian race	76 (80.9)	348 (79.6)	0.14
Distance to surgical center			
<200 miles	90 (95.7)	406 (88.6)	0.04
Insurance			
Private	62 (66.0)	220 (48.0)	0.002
College graduate (%)	22.8 (13.7–32.8)	21.5 (11.6–36.4)	0.36
<12.4 (<25th percentile)	15 (16.1)	120 (26.8)	0.03
Median family income (US\$)	63,611(50,079–73,565)	60,752 (43,936–78,098)	0.54
<45,694 (<25th percentile)	15 (16.1)	120 (26.8)	0.03
Cardiologist location			
Surgical center	42 (44.7)	134 (29.3)	0.004
Clinical characteristics			
Age at time of surgery (months)	0.8 (0.1–3.6)	2.6 (0.3–5.0)	0.0004
30 days	49 (52.1)	178 (38.9)	0.02
Premature, <37 weeks	10 (10.6)	74 (16.2)	0.17
Diagnosis severity			0.06
Mild	17 (18.1)	96 (21.0)	
Moderate	26 (27.7)	173 (37.8)	
Severe	51 (54.3)	189 (41.3)	
STAT category			0.04
Low (categories 1–3)	44 (46.8)	267 (58.3)	
High (categories 4–5)	50 (53.2)	191 (41.7)	
Hospital length of stay (days)	18.0 (10.0–30.0)	14.0 (8.0–25.0)	0.02
≤8 days	18 (19.1)	135 (29.5)	0.04
Extracorporeal membrane oxygenation	4 (4.3)	5 (1.1)	0.05
Non-cardiac anomaly	36 (38.3)	114 (24.9)	0.01
Genetic/chromosomal abnormality	23 (24.5)	120 (26.2)	0.73
Seizures/neurological disorders	18 (19.1)	49 (10.7)	0.02

STAT = Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery

\*Data presented as frequency (%) for categorical variables; median (interquartile range) for continuous variables

\*\*p-value from  $\chi^2$  test or Fisher's exact test for categorical variables and Wilcoxon rank sum test for continuous variables

have a median income below the 25th percentile ( $p=0.03$ ), and were less likely to be college graduates ( $p=0.03$ ) based on census block data. In addition, non-attendees were less likely to have private insurance ( $p=0.002$ ). There was no association between insurance type and distance from the surgical centre ( $p=0.65$ ).

### Multivariate analysis

In multivariable analysis (Table 3), lack of private insurance was the only factor that remained independently associated with non-attendance ( $p=0.01$ ). Non-attendance also tended to be associated with living  $\geq 200$  miles from our surgical centre ( $p=0.054$ ).

### Discussion

This single-centre, retrospective study identified a low rate of attendance in neurodevelopmental follow-up clinic for children with CHD who underwent

cardiac surgery in the first year of life. Lack of private insurance was associated with almost a twofold risk of non-attendance in our study. In addition, living farther from the surgical center tended to be associated with non-attendance. Multiple factors may influence loss to follow-up in paediatric populations. To our knowledge, this study is the first to evaluate and characterise risk factors associated with non-attendance for the CHD population.

### Prevalence of non-attendance

A scientific statement from the American Heart Association recommends that all children with CHD receive long-term neurodevelopmental surveillance.<sup>3</sup> The majority of our patients (83%), however, did not return for neurodevelopmental follow-up. Our findings are consistent with other studies documenting low rates of attendance in paediatric subspecialty or follow-up clinics.<sup>18,19,23,24</sup> In a retrospective review of very low birth weight infants, follow-up rates for patients enrolled in neonatal high-risk follow-up

Table 3. Risk factors for non-attendance in neurodevelopmental follow-up clinic in multivariable analysis.

	Adjusted odds ratio	95% confidence interval	p-value*
Distance from surgical site			
<200 miles	Reference		
≥200 miles	2.86	0.98–8.31	0.054
Insurance			
Private	Reference		
Non-private	1.85	1.14–3.04	0.01
Median family income (US\$)			
<45,694 (25th percentile)	1.59	0.85–2.97	0.14
≥45,694	Reference		
Age at time of surgery (days)			
<30 days	Reference		
≥30 days	1.35	0.74–2.49	0.33
STAT category			
Low (1–3)	1.26	0.70–2.28	0.44
High (4–5)	Reference		
Hospital length of stay (days)			
≤8 days	1.21	0.62–2.35	0.58
>8 days	Reference		
Non-cardiac anomaly	1.60	0.98–2.62	0.06
Seizure/neurological disorder	1.54	0.81–2.90	0.18

STAT = Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery

\*p-value from multivariable logistic regression

clinics were documented at 28%.<sup>19</sup> Within this study, inadequate insurance coverage and distance from the clinic site were documented reasons for low follow-up rates.<sup>19</sup> Return rates of <50% were documented for former neonates referred for continued high-risk developmental follow-up and continued subspecialty care.<sup>18</sup> Additionally, follow-up rates as low as 31% have been reported among newborns referred for additional audiology screening, with distance from clinic site and transportation and insurance coverage being cited as common barriers.<sup>23–25</sup>

#### *Lack of private insurance as a risk factor for non-attendance*

Lack of private insurance was the only independent factor associated with neurodevelopmental loss to follow-up in our study. Previous studies linked the lack of private insurance to low socio-economic status, increased barriers to accessing continued medical care, and loss to follow-up.<sup>26–29</sup> In a retrospective cohort study, Chang et al found that children with adequate public insurance coverage and Medicaid reimbursement were more likely to have poor follow-up compliance post cochlear implantation when compared with those with private insurance.<sup>27</sup> Furthermore, Skinner and colleagues also noted that

children with public insurance had access to speciality care, but were less likely to access this care when compared with individuals with private insurance.<sup>29</sup> These findings suggest that perhaps access to speciality care may be limited owing to decreased availability of resources – transportation, child care, etc. – encountered by patients from lower socio-economic statuses lacking private insurance. This is consistent with our findings from univariate analyses that non-attendees were more likely to live within a census block group with a family income below the 25th percentile.

#### *Distance from the site of neurodevelopmental evaluation as a risk factor for non-attendance*

Living >200 miles from the surgical center where neurodevelopmental evaluations were performed tended to be associated with non-attendance. Schultz and colleagues observed that distance from the neurodevelopmental testing site was an important factor in failure to complete neurodevelopmental follow-up at 1 year of age in multiple-gestation births in which one child had CHD.<sup>30</sup> Mussatto et al<sup>31</sup> also noted that non-attendees lived farther away than attendees and had less complex operations. As a large referral centre, many patients travel a long distance within and outside of our state for surgical repair, but may perceive travel for neurodevelopmental follow-up, which may not be available locally, as less important.

#### *Clinical characteristics as risk factors for non-attendance*

In our study, univariate analysis suggests that non-attendance was also associated with older age at surgery, lower surgical Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery risk categories, and shorter hospital length of stay. Previous studies have found that clinical and family factors such as severity of illness or parent's perceptions of their child's illness and perceived cost-benefit of appointments may influence paediatric follow-up rates.<sup>15,32</sup> In the CHD population, clinicians have observed that parents often focus on their child's heart disease and have lower developmental expectations.<sup>10</sup> Consistent with this observation, attendance is reported to be more common in cardiology clinics than in other sub-specialty clinics.<sup>15,33</sup> In our study, the absence of a non-cardiac anomaly tended to be associated with non-attendance. Perhaps the presence of additional non-cardiac anomalies motivated parents to seek further evaluation to identify potential neurodevelopmental deficits. Interestingly, the presence of a known genetic/chromosomal abnormality, a recognised risk factor for adverse neurodevelopmental outcomes, was not associated with

attendance at neurodevelopmental follow-up. These findings suggest that parents of children referred to our neurodevelopmental follow-up clinic may underestimate the importance of this evaluation. As a result, parents may focus on their child's heart disorder while overlooking other aspects of well-being and development.

### Limitations

This study encompassed the largest analysis to date evaluating factors associated with non-attendance with neurodevelopmental follow-up in the CHD population. However, important limitations must be considered. Being a single-centre study, our results may not be generalisable across all centres. Families may have moved and failed to receive reminder notices before scheduled appointments as appointments were often made well in advance of planned follow-up at 9–12 months of age. Furthermore, some infants may have received developmental screening and/or services through local, state-supported early intervention programmes, which parents perceived as sufficient. In addition, as data collection was limited to chart review and census data, further detailed assessments of parental attitudes and beliefs towards the importance of neurodevelopmental behaviours, of individual family circumstances/resources (including insurance coverage of developmental or mental health services), and other family factors could not be captured. This will require further study and we are currently prospectively attempting to elicit reasons for neurodevelopmental clinic appointment cancellation. Finally, while our methodology using census block groups has been widely used in other similar studies, we were limited to inferring that a patient's block group represents his/her socio-demographic status based on the last known address. This study, however, was a necessary first step in addressing this important issue of neurodevelopmental follow-up.

### Conclusion

Neurodevelopmental follow-up is recommended for children with congenital heart surgery during infancy. Lack of private insurance, which may be a marker of other social risk factors, was a significant risk factor for non-attendance at neurodevelopmental follow-up evaluation. Furthermore, parents may not understand that risk of adverse neurodevelopmental outcomes is not based solely on CHD severity. Our findings suggest the need to minimise barriers to follow-up for families and to better educate parents regarding their child's neurodevelopmental risk.

On the basis of the findings from this study, we have modified our practice in several ways in an

attempt to augment the rate of follow-up. Practice changes include calling to remind families of the scheduled visit, providing further information regarding the importance of follow-up, and eliciting reasons for cancellation. We have also launched a developmental care initiative to promote and model practices to support infant development during hospitalisation and to emphasise the importance of ongoing neurodevelopmental evaluation. Further research is needed to understand the impact of these initiatives, and to better understand ways through which neurodevelopmental evaluation and follow-up can be delivered, integrated, and encouraged as part of standard care to individuals with CHD starting from infancy.

### Acknowledgements

None.

### Financial Support

This research received no specific grant from any funding agency, commercial, or not-for-profit sectors.

### Conflicts of Interest

None.

### Ethical Standards

None.

### References

1. Upham M, Medoff-Cooper B. What are the responses & needs of mothers of infants diagnosed with congenital heart disease? *MCN Am J Matern Child Nurs* 2005; 30: 24–29.
2. Jerrell JM, Shuler CO, Tripathi A, Black GB, Park Y-MM. Long-term neurodevelopmental outcomes in children and adolescents with congenital heart disease. *Primary Care Companion CNS Disord* 2015; 17: 5, <https://doi.org/10.4088/PCC.4015m01842>.
3. Marino BS, Lipkin PH, Newburger JW, et al. Neurodevelopmental outcomes in children with congenital heart disease: evaluation and management: a scientific statement from the American Heart Association. *Circulation* 2012; 126: 1143–1172.
4. Gaynor JW, Stopp C, Wypij D, et al. Neurodevelopmental outcomes after cardiac surgery in infancy. *Pediatrics* 2015; 135: 816–825.
5. Donofrio MT, Massaro AN. Impact of congenital heart disease on brain development and neurodevelopmental outcome. *Int J Pediatr* 2010; 2010: 13 pages, doi:10.1155/2010/359390.
6. Hövels-Gürich HH, Seghaye M-C, Däbritz S, Messmer BJ, von Bernuth G. Cognitive and motor development in preschool and school-aged children after neonatal arterial switch operation. *J Thorac Cardiovasc Surg* 1997; 114: 578–585.
7. Khalil A, Suff N, Thilaganathan B, Hurrell A, Cooper D, Carvalho JS. Brain abnormalities and neurodevelopmental delay in congenital heart disease: systematic review and meta-analysis. *Ultrasound Obstet Gynecol* 2014; 43: 14–24.
8. Majnemer A, Limperopoulos C. Developmental progress of children with congenital heart defects requiring open heart surgery. *Semin Pediatr Neurol* 1999; 6: 12–19.

9. Massaro AN, El-Dib M, Glass P, Aly H. Factors associated with adverse neurodevelopmental outcomes in infants with congenital heart disease. *Brain Dev* 2008; 30: 437–446.
10. Brosig C, Mussatto K, Hoffman G, et al. Neurodevelopmental outcomes for children with hypoplastic left heart syndrome at the age of 5 years. *Pediatr Cardiol* 2013; 34: 1597–1604.
11. Cassidy AR, White MT, DeMaso DR, Newburger JW, Bellinger DC. Executive function in children and adolescents with critical cyanotic congenital heart disease. *J Int Neuropsychol Soc* 2015; 21: 34–49.
12. Chock V, Lee HC. Neurodevelopmental outcomes for infants born with congenital heart disease. *NeoReviews* 2014; 15: e344–e353.
13. Sananes R, Manlhiot C, Kelly E, et al. Neurodevelopmental outcomes after open heart operations before 3 months of age. *Ann Thorac Surg* 2012; 93: 1577–1583.
14. Snookes SH, Gunn JK, Eldridge BJ, et al. A systematic review of motor and cognitive outcomes after early surgery for congenital heart disease. *Pediatrics* 2010; 125: e818–e827.
15. Andrews R, Morgan JD, Addy DP, McNeish AS. Understanding non-attendance in outpatient paediatric clinics. *Arch Dis Childhood* 1990; 65: 192–195.
16. Guzek LM, Fadel WF, Golomb MR. A pilot study of reasons and risk factors for “No-Shows” in a pediatric neurology clinic. *J Child Neurol* 2015; 30: 1295–1299.
17. Specht EM, Powell KR, Dormo CA. Factors affecting missed appointment rates for pediatric patients insured by medicaid in a traditional hospital-based resident clinic and hospital-owned practice settings. *Clin Pediatr* 2004; 43: 749–752.
18. Bruni R, Bahamonde LG, Gupta M, Findlay RD, Bean X. Long-term follow up of NICU graduates: social variables, not clinical problems, determine drop-out rates and access to health care. *Pediatr Res* 1998; 43: 208.
19. Patra K, Greene M, Perez B, Silvestri JM. Neonatal high-risk follow-up clinics: how to improve attendance in very low birth weight infants. *J Neonatol Res* 2014; 4: 3–13.
20. Yoon EY, Davis MM, Van Cleave J, Maheshwari S, Cabana MD. Factors associated with non-attendance at pediatric subspecialty asthma clinics. *J Asthma* 2005; 42: 555–559.
21. Roberts G, Howard K, Spittle AJ, Brown NC, Anderson PJ, Doyle LW. Rates of early intervention services in very preterm children with developmental disabilities at age 2 years. *J Paediatr Child H* 2008; 44: 276–280.
22. Wernovsky G. Current insights regarding neurological and developmental abnormalities in children and young adults with complex congenital cardiac disease. *Cardiol Young* 2006; 16 (Suppl 1): 92–104.
23. Hunter LL, Meinzen-Derr J, Wiley S, Horvath CL, Kothari R, Wexelblatt S. Influence of the WIC program on loss to follow-up for newborn hearing screening. *Pediatrics* 2016; 138: 1.
24. Kanji A, Khoza-Shangase K, Ballot D. Hearing screening follow-up return rate in a very low birth weight project: a retrospective record review. *South African Journal of Child Health* 2010; 4: 95.
25. Loss to Follow-Up in early hearing detection and intervention [Technical Report]. American Speech-Language-Hearing Association. (2008). Retrieved from [www.asha.org/policy](http://www.asha.org/policy).
26. Boss EF, Benke JR, Tunkel DE, Ishman SL, Bridges JF, Kim JM. Public insurance and timing of polysomnography and surgical care for children with sleep-disordered breathing. *JAMA Otolaryngol Head Neck Surg* 2015; 141: 106–111.
27. Chang DT, Ko AB, Murray GS, Arnold JE, Megerian CA. Lack of financial barriers to pediatric cochlear implantation: impact of socioeconomic status on access and outcomes. *Arch Otolaryngol Head Neck Surg* 2010; 136: 648–657.
28. Park CH, Kogan MD, Overpeck MD, Casselbrant ML. Black-white differences in health care utilization among US children with frequent ear infections. *Pediatrics* 2002; 109: E84.
29. Skinner AC, Mayer ML. Effects of insurance status on children’s access to specialty care: a systematic review of the literature. *BMC Health Serv Res* 2007; 7: 194.
30. Schultz AH, Jarvik GP, Wernovsky G, et al. Effect of congenital heart disease on neurodevelopmental outcomes within multiple-gestation births. *J Thorac Cardiovasc Surg* 2005; 130: 1511–1516.
31. Mussatto KA, Hoffmann RG, Hoffman GM, et al. Risk and prevalence of developmental delay in young children with congenital heart disease. *Pediatrics* 2014; 133: e570–e577.
32. McPherson ML, Lairson DR, Smith EO, Brody BA, Jefferson LS. Noncompliance with medical follow-up after pediatric intensive care. *Pediatrics* 2002; 109: e94.
33. Cameron E, Heath G, Redwood S, et al. Health care professionals’ views of paediatric outpatient non-attendance. *Family Practice* 2014; 31: 111–117.